Altimmune (ALT) Stock Forecast & Price Target

Altimmune is a promising biopharmaceutical company that has a unique and differentiated drug candidate, pemvidutide, that targets both glucagon and GLP-1 receptors. With potential treatments for serious liver diseases such as MASH, AUD, and ALD, Altimmune has multiple near-term value-creation opportunities with its RECLAIM and PERFORMA trials, as well as the recent completion of enrollment for its RESTORE trial. Their strong financial position, with over $340 million in pro-forma cash, and partnerships with regulatory bodies further solidify a positive outlook for Altimmune's future success.

Altimmune is heavily reliant on the success of pemvidutide, which faces competition from more advanced candidates and may have difficulty gaining market penetration if one of these competitors receives approval; the integration of AIM-MASH AI Assist into the histologic assessment could lead to a statistical power upside, but it is still in early stages and may not mitigate the high placebo response; and with a delayed planned initiation for Ph3 MASH, it may be several years before pemvidutide can generate significant revenue, potentially impacting the company's solvency and stock performance.